Mylan to Address Two Patent Suits in Delaware

Mylan will face two separate patent infringement suits in Delaware, a three-judge panel from the U.S. Court of Appeals for the Federal Circuit ruled last week.

The first suit concerns Mylan’s efforts to contest Acorda’s patents on the multiple sclerosis drug Ampyra, which Alkermes manufactures for it. In January 2014, Mylan filed an ANDA with the FDA to market a generic version of the drug, certifying that Acorda’s patents either are invalid or inapplicable.

Another suit brought by AstraZeneca contends that Mylan threatened patents it holds on the diabetes meds Onglyza and Kombiglyze by filing ANDAs to market generic versions of those drugs as well.